Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-964-5788
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions
What is Marina Biotech's stock symbol?
Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."
How were Marina Biotech's earnings last quarter?
Marina Biotech, Inc. (OTCMKTS:MRNA) issued its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.06. The biotechnology company earned $17.05 million during the quarter, compared to the consensus estimate of $17.64 million. The company's revenue for the quarter was down 59.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.24) EPS. View Marina Biotech's Earnings History.
What price target have analysts set for MRNA?
6 Wall Street analysts have issued 12-month price targets for Marina Biotech's shares. Their forecasts range from $24.00 to $40.00. On average, they expect Marina Biotech's stock price to reach $30.60 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. View Analyst Price Targets for Marina Biotech.
What is the consensus analysts' recommendation for Marina Biotech?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marina Biotech.
Has Marina Biotech been receiving favorable news coverage?
Headlines about MRNA stock have trended somewhat negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Marina Biotech earned a news impact score of -1.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Marina Biotech.
Who are some of Marina Biotech's key competitors?
Some companies that are related to Marina Biotech include UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Beigene (BGNE), Ionis Pharmaceuticals (IONS) and Jazz Pharmaceuticals (JAZZ).
What other stocks do shareholders of Marina Biotech own?
Who are Marina Biotech's key executives?
Marina Biotech's management team includes the folowing people:
- Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)
- Mr. Robert C. Moscato Jr., CEO & Director (Age 42)
- Mr. Amit Shah, Chief Financial Officer (Age 52)
- Mr. Mihir Munsif, Chief Operating Officer (Age 55)
- Dr. Larn Hwang, Chief Scientific Officer (Age 55)
Who are Marina Biotech's major shareholders?
Marina Biotech's stock is owned by many different of retail and institutional investors. Top institutional investors include Moloney Securities Asset Management LLC (0.04%), Boston Advisors LLC (0.01%) and Parallel Advisors LLC (0.00%). Company insiders that own Marina Biotech stock include Lorence H Kim, Peter Barton Hutt and Stephane Bancel. View Institutional Ownership Trends for Marina Biotech.
Which major investors are selling Marina Biotech stock?
MRNA stock was sold by a variety of institutional investors in the last quarter, including Parallel Advisors LLC. Company insiders that have sold Marina Biotech company stock in the last year include Lorence H Kim, Peter Barton Hutt and Stephane Bancel. View Insider Buying and Selling for Marina Biotech.
Which major investors are buying Marina Biotech stock?
What is Marina Biotech's stock price today?
One share of MRNA stock can currently be purchased for approximately $18.65.
How big of a company is Marina Biotech?
What is Marina Biotech's official website?
How can I contact Marina Biotech?
Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]
MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)
MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
